Business · 12/08/1999Updated: 10/17/2026 · 1 min read

Criteria for Safety and Efficacy Evaluation of Oxygen Therapeutics as Red Cell Substitutes; Public Workshop

Summary

Oxygen Therapeutics will hold a public workshop to discuss the criteria for evaluating the safety and efficacy of its red cell substitutes. The workshop aims to provide a platform for stakeholders to share their views on the evaluation process.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News Central Bank Policy News

Related business signals

Business · 9/16/2026

Medicare Program; Public Meeting for New Revisions to the Healthcare Common Procedure Coding System (HCPCS) Level II Coding

The Centers for Medicare and Medicaid Services (CMS) will hold its second biannual Healthcare Common Procedure Coding System (HCPCS) Level II public meeting of 2026 to discuss new revisions to the HCPCS Level II code set for non-drug and non-biological items and services.

Read summary →

Business · 9/16/2026

Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencing

The Food and Drug Administration (FDA) announces a public advisory committee meeting of the Microbiology Devices Panel to discuss pathogen-agnostic sequencing for emergency preparedness and response efforts.

Read summary →

Business · 9/15/2026

FDA Establishes Public Docket for Rare Disease Clinical Investigations Statistical Considerations

The FDA is collecting feedback on statistical considerations for rare disease clinical investigations through a public docket, which is open until a certain date, and a Rare Disease Innovation, Science, and Exploration (RISE) Workshop on the topic.

Read summary →

Business · 9/15/2026

National Cancer Institute Considers Exclusive Patent License for Engineered Cell Therapies for HPV 16 E6-Expressing Cancers

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to MedGene Therapeutics, Inc., a Maryland-based company, to develop and commercialize engineered cell therapies for treating cancers caused by the HPV 16 E6 gene.

Read summary →

Business · 10/5/2026

CDC Invites Public Comment on Proposed Data Collection for Public Health Crisis Response

The Centers for Disease Control and Prevention (CDC) is seeking public feedback on a proposed data collection project, titled Public Health Crisis Response (PHCR) Cooperative Agreement, which aims to rapidly fund public health programs responding to major emergencies and crises, as required by the Paperwork Reduction Act of 1995.

Read summary →

Business · 10/5/2026

CDC Requests Public Comment on Respiratory Protective Devices Data Collection

The Centers for Disease Control and Prevention (CDC) is seeking public input on a proposed data collection project related to Respiratory Protective Devices, as required by the Paperwork Reduction Act of 1995, to inform the approval certification activities under 42 CFR part 84.

Read summary →